Annovis Bio, Inc.
Annovis Bio, Inc. (Nasdaq: ANVS) is a late-stage clinical drug development company focused on addressing neurodegeneration, particularly Alzheimer's disease and Parkinson's disease. The company's website is www.annovis.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Annovis Bio, Inc. does
In the company’s own words
Annovis Bio, Inc. (Nasdaq: ANVS) is a late-stage clinical drug development company focused on addressing neurodegeneration, particularly Alzheimer's disease and Parkinson's disease. The company's website is www.annovis.com.
The company's lead product candidate, buntanetap, is an orally administered, brain-penetrant small molecule designed to inhibit the synthesis of neurotoxic proteins including APP/Aβ, tau/phospho-tau, α-Synuclein, and TDP43. These proteins are believed to be primary drivers of neurodegeneration. Buntanetap operates through a novel mechanism of action as a translational inhibitor, targeting an atypical stem loop region in the messenger RNA of neurotoxic aggregating proteins. By preventing overexpression of these proteins, the drug is designed to reverse the downstream toxic cascade that leads to neurodegeneration and restore nerve cell function.
Annovis has completed twelve clinical studies to date, including Phase 1/2 trials in early Alzheimer's and Parkinson's patients and a Phase 2/3 trial in mild to moderate Alzheimer's patients. The company initiated a pivotal Phase 3 trial in early Alzheimer's disease in February 2025, enrolling 760 patients across 83 U.S. sites. The trial incorporates a six-month symptomatic efficacy component followed by a twelve-month extension to evaluate disease-modifying potential. Additionally, the company began an open-label extension study in Parkinson's disease patients in January 2026, designed to enroll 500 patients for long-term safety and efficacy evaluation.
The company's pipeline also includes ANVS405, an intravenous formulation of buntanetap for acute neurological indications such as traumatic brain injury and stroke, and ANVS301, an oral candidate for advanced Alzheimer's disease and dementia. Over 1,200 human patients have been treated with buntanetap across clinical studies, with the drug consistently demonstrating good tolerability and minimal side effects. Annovis was founded in May 2008 and operates as a clinical-stage biopharmaceutical company with no approved products currently on the market.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1477845
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Annovis Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Annovis Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Annovis Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Annovis Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Annovis Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”